Applied DNA Positions TR8 PGx Testing Service as Pre-emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement
April 1st, 2025
Applied DNA Positions TR8 PGx Testing Service as Pre-emptive Testing for Safety of Fluoropyrimidine-Based Cancer Therapeutics Following Publication of Food and Drug Administration Safety Announcement
April 1st, 2025
Applied DNA Partners with GenXys Health Care Systems to Deploy Clinical Decision Support System for Pharmacogenetic (PGx) Testing
June 18th, 2024
Applied DNA Receives Approval for TR8™ Pharmacogenomic (PGx) Testing Service from New York State Department of Health
June 13th, 2024